Latest Interviews
Showing 1–6 of 6 transcripts.
Clear all filters- a16z10 min
Disrupt Yourself
The speaker frames the current transition in life sciences as an industrial revolution where biology shifts from artisanal discovery to engineered automation, urging leaders to proactively disrupt themselves before market forces do. Drawing parallels to strategic pivots by Jensen Huang at Nvidia and Steve Jobs with AT&T, the presentation defines corporate survival as a form of social engineering that prioritizes future ecosystems over existing profitability. Ultimately, the event calls for redefining healthcare and entertainment as technology sectors to fundamentally reshape illness prevention and treatment.
- a16z8 min
a16z Podcast | On Recent Consolidation in the Healthcare Industry
Jorge Conde, Vijay Pande, Jeffrey Low
Major healthcare players are driving industry consolidation through vertical integration strategies exemplified by Walmart's potential Humana acquisition and the Amazon-JP Morgan-Berkshire consortium. These moves aim to collapse the value chain from manufacturers to insurers, though speakers distinguish between locally dominant retailers and geographically dispersed employer groups regarding their pricing power. As Amazon targets opaque PBM margins without acquiring marquee assets, the market anticipates new entrepreneurial opportunities in specialized genomic and cell therapy logistics to manage rising treatment costs.
- a16z17 min
a16z Podcast | The Business of Healthcare
Rajeev Singh, Vijay Pande, Sean Duffy
Driven by a projected rise in healthcare spending to 19% of GDP and a critical Type 2 diabetes epidemic, the industry is pivoting toward value-based care models led by firms like Omada and Accolade. These companies differentiate themselves through a hybrid tech-persona approach that pairs digital tools with human coaching, securing competitive moats via longitudinal clinical data rather than traditional patent protections. By rejecting fee-for-service structures in favor of outcomes-based pricing and navigating complex regulatory environments, these organizations aim to establish chronic disease management as a mandatory standard of care for a significant portion of the U.S. population within the next five years.
- a16z14 min
a16z Podcast | The Genetics Of Drug Delivery
Stanford professor Russ Altman leads a data science laboratory that integrates molecular, cellular, and population-level data to optimize drug response and identify previously unknown side effects. By analyzing diverse sources ranging from electronic medical records to web search logs, Altman's team successfully uncovered critical interactions, such as a glucose spike caused by combining paroxetine and pravastatin, and predicted new therapeutic uses for existing cancer drugs. This multi-scale approach, supported by funding from the National Institutes of Health and industry partners like Pfizer and Genentech, aims to replace fragmented clinical trial models with continuous, data-driven surveillance for safer and more effective pharmaceutical development.
- a16z8 min
Consolidation in Healthcare: What to Make of It?
Jorge Conde, Vijay Pande, Jeffrey Low
Leading healthcare entities are pursuing divergent consolidation strategies, exemplified by Walmart's potential acquisition of Humana to create a vertically integrated retail-insurance model, while Amazon, Berkshire Hathaway, and JPMorgan develop a dispersed employer consortium. Analysts predict that local integration offers more immediate cost reductions than geographically scattered employer alliances, prompting new market entrants to build proprietary pharmacy benefit management capabilities and specialized logistics for complex gene and cell therapies. This sector-wide shift toward vertical monoliths and advanced therapeutic infrastructure is creating entrepreneurial opportunities focused on digital therapeutic reimbursement and friction-free administrative frameworks.
- a16z13 min
On Machine Learning in Medicine and More
Andreessen Horowitz is distinguishing its bio-investing strategy by applying software methodologies and machine learning to traditional biological challenges, specifically targeting digital therapeutics, computational medicine, and cloud biology infrastructure. This approach leverages hybrid founders with dual expertise in computer science and biology to de-risk drug development, enabling scalable solutions that integrate with existing healthcare systems while projecting software-like returns. By transforming healthcare from acute intervention to preventative maintenance through advanced data analytics, the firm aims to secure exit multiples significantly higher than those typical of conventional life sciences ventures.